Emerald Health Therapeutics’ Scientific Advisors Publish Research Discovery of THCA Cannabinoid’s Neuroprotective Treatme...
September 20 2017 - 7:00AM
Emerald Health Therapeutics Inc. (EHT) (TSXV:EMH) (OCTQX:EMHTF), a
Canadian licensed medical producer of cannabis, is pleased to
report that members of its scientific advisory team have made a
novel discovery highlighting the potential of
tetrahydrocannabinolic acid (THCA), a naturally occurring
non-psychotropic cannabinoid, to treat Huntington’s disease and
other metabolic, neurodegenerative and neuroinflammatory diseases.
These results were published in the British Journal of Pharmacology
in a peer-reviewed article entitled, “Tetrahydrocannabinolic acid
is a potent PPARγ agonist with neuroprotective activity.”
This recent article in the British Journal of
Pharmacology focused on the activity of Δ9-THCA, one of the most
common cannabinoids (and a non-psychotropic precursor of THC), on
PPARγ. PPARγ signalling has a role in neuroinflammation and
epilepsy. Δ9-THCA is a potent PPARγ agonist and in this study
exhibited neuroprotective and anti-neuroinflammatory activity in an
animal model of Huntington´s disease.
This research was conducted at Instituto
Maimónides de Investigación Biomédica de Córdoba (IMIBIC).
Co-authors of this paper included EHT scientific advisory board
members Eduardo Muñoz, MD, PhD, Professor of Immunology at
University of Córdoba; Giovanni Appendino, PhD, Professor of
Pharmaceutical Chemistry at University of Eastern Piedmont; and
Gaetano Morello, ND, clinician, Complex Chronic Disease Program, BC
Women’s Hospital.
“A large number of patients suffer from
neurodegenerative diseases and they are not responsive to available
medical treatments. Our research data provide further evidence that
cannabinoids hold therapeutic potential for a wide range of
diseases and conditions, including neurodegeneration, which
represents a significant unmet medical need,” said Eduardo Muñoz,
PhD, EHP’s Chief Scientific Officer, Professor of Immunology at the
University of Córdoba, and corresponding author of the paper.
“It is very encouraging to see the successful
effort of Drs. Muñoz and Appendino, who stand in a small circle of
international scientific pioneers who have worked on cannabinoid
research for well over a decade. We applaud their ground-breaking
research on THCA and being published in this leading pharmacology
journal,” said Frey Garabagi, PhD, Vice President of R&D of
EHT. “We are pleased to be one of the first and few companies to
offer THCA cannabis oil and look forward to generating human data
from clinical research we are planning for this product in the near
future.”
Join us on our journey of making lives better through
cannabis science.
About Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. (TSXV:EMH)
(OTCQX:EMHTF) operates primarily through Emerald Health Botanicals
Inc. ("Botanicals"), a wholly owned subsidiary and Licensed
Producer under the Access to Cannabis for Medical Purposes
Regulations. Botanicals is authorized to produce and sell both
dried medical cannabis flower and medical cannabis oil in Canada.
Botanicals currently operates an indoor facility in Victoria, BC,
and is progressing on expansion plans for a 32-acre property in
Metro Vancouver and a joint venture with Village Farms, called Pure
Sunfarms, utilizing a 25 acre existing greenhouse complex in Delta,
BC. Botanicals is one of Canada's most medically focused licensed
producers, with a team highly experienced in life sciences product
development and large-scale agribusiness. Its vision is to be a
leading provider of cannabis products through its production
capabilities, proprietary genetics, value-added products and
branding, and superb customer experience. Emerald Health
Therapeutics is part of the Emerald Health group, which comprises
multiple companies advancing diverse botanical, nutraceutical and
pharmaceutical products that may provide wellness and medical
benefits by interacting with the body’s endocannabinoid system.
For investor and media contacts:
invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Statements Regarding Forward
Looking Information
Certain statements in this press release
constitute forward-looking statements, within the meaning of
applicable securities laws. All statements that are not
historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, are "forward-looking statements".
We caution you that such "forward-looking
statements" involve known and unknown risks and uncertainties that
could cause actual and future events to differ materially from
those anticipated in such statements.
Forward-looking statements include, but are not
limited to, statements with respect to legalization of
non-therapeutic cannabis sales in Canada; participation in the
legalized non-therapeutic cannabis industry; growth in the
extract-based market; increased production of cannabis; commercial
operations; construction or conversion of production facilities;
applications for licensing; obtaining such licenses; commencement
of production of cannabis at the Company’s facilities; estimates of
production capacity at such facilities; contributions of cash to
the JV; international opportunities for the Company; commencement
of clinical trials; the Company becoming a leading Canadian
supplier of cannabis products; expected timing of any of the above
matters; and other information that is based on forecasts of future
results, estimates of amounts not yet determinable and assumptions
of management.
Emerald Health Therapeutics Inc. does not
intend, and does not assume any obligation, to update these
forward-looking statements except as required by law. These
forward-looking statements involve risks and uncertainties relating
to, among other things, failure of the federal government to
approve legislation legalizing sales of non-therapeutic adult-use
cannabis; failure to obtain Health Canada and other regulatory
approvals; failure to obtain necessary financing; results of
production and sale activities; the Company's historical experience
with medical marijuana operations; results of scientific research;
uninsured risks; regulatory changes; difficulties in construction
or in obtaining qualified contractors to complete construction or
conversion of facilities; availability of production facilities;
timeliness of government approvals and the granting of permits and
licenses; changes in prices and costs; actual operating and
financial performance of facilities; equipment and processes
relative to specifications and expectations; as well as the other
risk factors set out in the Company’s annual information form and
other filing with the applicable Canadian securities regulators,
which may be viewed at www.sedar.com. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2023 to Apr 2024